## Vijayananda Kundapur

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3545702/publications.pdf

Version: 2024-02-01

23 papers

1,868 citations

933447 10 h-index 17 g-index

23 all docs 23 docs citations

times ranked

23

2223 citing authors

#	Article	IF	CITATIONS
1	Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial. Journal of Clinical Oncology, 2014, 32, 3810-3816.	1.6	894
2	Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. Journal of Clinical Oncology, 2020, 38, 1019-1029.	1.6	483
3	Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology–RTOG 1203. Journal of Clinical Oncology, 2018, 36, 2538-2544.	1.6	231
4	Risk of Hippocampal Metastases in Small Cell Lung Cancer Patients at Presentation and After Cranial Irradiation: A Safety Profile Study for Hippocampal Sparing During Prophylactic or Therapeutic Cranial Irradiation. International Journal of Radiation Oncology Biology Physics, 2015, 91, 781-786.	0.8	55
5	A Phase III Randomized Trial Comparing Patient-Reported Toxicity and Quality of Life (QOL) During Pelvic Intensity Modulated Radiation Therapy as Compared to Conventional Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, S3.	0.8	34
6	Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non–Small-Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial. Clinical Lung Cancer, 2017, 18, 250-254.	2.6	32
7	CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933. Journal of Neuro-Oncology, 2016, 126, 327-336.	2.9	31
8	NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM) Journal of Clinical Oncology, 2019, 37, 2009-2009.	1.6	31
9	Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933. Advances in Radiation Oncology, 2019, 4, 579-586.	1.2	17
10	Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy. Gynecologic Oncology, 2019, 154, 183-188.	1.4	13
11	Collimator design for experimental minibeam radiation therapy. Medical Physics, 2011, 38, 2192-2197.	3.0	12
12	Planning Target Volume Margin Evaluation and Critical Structure Sparing for Rectal Cancer Patients Treated Prone on a Bellyboard. Clinical Oncology, 2013, 25, e17-e22.	1.4	10
13	Hippocampus Avoidance Whole-brain Radiation Therapy: A Practical Intensity-modulated Radiation Therapy Planning and Delivery Approach toÂRTOG 0933. Journal of Medical Imaging and Radiation Sciences, 2015, 46, 78-84.	0.3	10
14	Using $kV-kV$ and CBCT imaging to evaluate rectal cancer patient position when treated prone on a newly available belly board. Medical Dosimetry, 2012, 37, 117-121.	0.9	8
15	Dosimetric characterization of an accessory mounted mini-beam collimator across clinically beam matched medical linear accelerators. Biomedical Physics and Engineering Express, 2017, 3, 015014.	1.2	3
16	Evaluating QUANTEC Small Bowel Dose-Volume Guidelines for Rectal Cancer Patients Treated Using a Couch Top Inclined Belly Board. Journal of Medical Imaging and Radiation Sciences, 2014, 45, 218-222.	0.3	2
17	PO-0867: Treatment planning study for spatially fractionated minibeam radiotherapy. Radiotherapy and Oncology, 2016, 119, S414.	0.6	1
18	Can hippocampus be spared in patients with small cell lung carcinoma (SCLC) during cranial radiation therapy (CRT)?. Journal of Clinical Oncology, 2013, 31, 7596-7596.	1.6	1

#	Article	IF	CITATIONS
19	NCO-14PRE-TREATMENT HIPPOCAMPAL VOLUME PREDICTS NEUROCOGNITIVE FUNCTION (NCF) FOR PATIENTS TREATED WITH HIPPOCAMPAL AVOIDANCE WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0933. Neuro-Oncology, 2015, 17, v149.1-v149.	1.2	O
20	Clinicians Underreport Adverse Events in NRG Oncology's Radiation Therapy Oncology Group 1203: The Importance of Using Patient-Reported Outcomes in Oncology Clinical Trials. International Journal of Radiation Oncology Biology Physics, 2016, 96, S125.	0.8	0
21	87: Can we Reduce Normal Tissue Radiation Exposure? – A Craniospinal Irradiation Technique without Junction Matching using Varian Eclipse Platform. Radiotherapy and Oncology, 2016, 120, S34.	0.6	0
22	Sci-Thur PM - Colourful Interactions: Highlights 01: Design to delivery of spatially fractionated mini-beam canine radiotherapy. Medical Physics, 2016, 43, 4931-4931.	3.0	0
23	Poster - 23: Dosimetric Characterization and Transferability of an Accessory Mounted Mini-Beam Collimator. Medical Physics, 2016, 43, 4941-4941.	3.0	O